<?xml version="1.0" encoding="UTF-8"?>
<p>By 1994, 10 y after the first descriptions of infected children, the epidemic was progressing inexorably, and its catastrophic scale in sub-Saharan Africa was evident. At the same time, the first monotherapy treatments using nucleoside analogs proved to be very disappointing and only marginally influenced the course of the disease. It is in this very pessimistic context that the interim analysis of a placebo-controlled USâ€“French protocol to prevent transmission during pregnancy by zidovudine (ACTG076-ANRS024) provided the first stunning success of antiretroviral therapy: oral zidovudine administered 
 <italic>prepartum</italic>, intravenously during labor, and then 
 <italic>postpartum</italic> in the child reduced the risk of transmission to the child by two-thirds [
 <xref rid="CIT0016">16</xref>]. This unexpected result led to the immediate interruption of the trial and opened a new era of hope that has been growing since through the exceptional mobilization of institutes, associations, and individuals. Twenty-five years later, it is possible to seriously consider the unimaginable: the possible eradication of pediatric AIDS [
 <xref rid="CIT0017">17</xref>].
</p>
